Pratical aspects in the prevention and treatment of postmenopausal;Aspectos práticos na prevenção e tratamento da osteoporose pós-menopausa

Revista Brasileira de Medicina

Volumn 58, Issue 6, 2001, Pages 385-393

  Hegg, Roberto ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE

Author keywords

Ossein hydroxyapatite; Osteoporosis; Postmenopausal

Indexed keywords

CALCIUM CARBONATE; HYDROXYAPATITE; VITAMIN D;

DIET SUPPLEMENTATION; EXERCISE; HORMONE SUBSTITUTION; HUMAN; OSTEOPOROSIS; PATIENT COUNSELING; POSTMENOPAUSE; PREVALENCE; REVIEW; RISK FACTOR; SUN EXPOSURE;

EID: 0343772992     PISSN: 00347264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Alioa JF, Vaswani A Yeh JK, et al. Calcitriol in treatment of postmenopausal osteoporosis. Am J Med, 1989; 84:401.
2. Annefeld M, Caviezel R, Shacht E, Schicketanz KH. The influence of ossein-hydroxyapatite compoud ("Ossopan") on the healing of the a bone defect. Curr Med Res Opin, 1996; 10:241-50.
3. Berard A, Bravo G, Gauthier P. Meta-analysis of the effectiveness of physical activity for the prevention of bone loss in postmenopausal women. Osteoporos. In. 1997; 7(4): 331-7.
4. Balfour JA, Goa KL. Raloxifeno Drugs Aging 1998; 12:335-41; discussion 342.
5. Birdwood G, Susceptibillity to osteoporosis, In (ed), Understanding osteoporosis and its treatment. A guide for physicians and their patients. New York, Parthenon, 1996. P.69.
6. Bone HG, Greenspan SL, Mckeever C, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate Estrogen Study Group. J Clin Endocrinol Metab, 2000; 85(2): 720.
7. Boonekamp PM, Van Der Weepals, LJA, Van Wijkvan Lennep M, et al. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Mineral, 1986 ;1:27-40.
8. Boujour J.P & Theintz G. "Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolecence". J. Clin Endocrinol. Metab., 1991; 73:555-63.
9. Castelo-Branco C, Osaba MJM, Pons F, Casis E, Sanjuán A, Vicente JJ, Varell JA. Coadjuvant use of ossein-hydroxyapatite compouds in subjects on hormone replacement therapy for prevention of postmenopausal bone loss 1998.
10. Cavanaugh, D, Cannce. Brisk walking does stop bone loss in postmenopausal women. Bone, 1988; 9:201.
11. Chapuy MC, Arlot ME, Duboelf F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ. Vitamin D3 and calcium to prevent hip fractures in elderly women. New Engl J Med, 1992; 327:1637.
12. Chavassieux P, Pastoureau P, Boivin G, Delamas PD, Chapuy MC, Meunier PJ. Effects of osseinhydroxyapatite compoud on ewe bone remodeling: Biochemical and histomorphometric study. Clin Reumathol, 1991; 10:269-73.
13. Chevalley T, Rizzoli R, Nydegger V, et al. Effects of calcium supplements on femural bone mineral density and vertebral fracture rate invitamin D -replete elderly patients. Osreoporos Int, 1994; 4: 245.
14. Chow R K,. Physical fitness effect on bone mass in potmenopausal women. Arch. Pitys. Med. Rehabill. 1986; 67: 231-4.
15. Christiansen C, Christiansen M S & Larsen NE. Pathophysiological mechanism of estrogens effect on bone metobolism. Dose response relationship in early postmenopausal women. J. Clin Endocr. Metab. 1982; 55:1124.
16. Christiansen C, Christiansen MS, Rodbro P. Effect of 1,25 dihydroxy vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis. Eur J Clin Invest 1981; 11:305.
17. Cohen-Solal ME, Roux C, Valentin-Opran A, et al. Hitomorphometriceffect in patients with multiple myeloma. Bone, 1993; 14:505-509.
18. Consensus Development Conference. Prophylaxis and treatment of osteoporosis. Am J Med, 1991; 90:107.
19. Consensus Development Conference. Diagnosis, Prophylaxix, and Treatment of Ostoporosis. Am J. Med 1993; 94:646.
20. Cooper C, Campion G, Melton III LJ,. Hip fractures in the elderly: world-projection. Osteoporos Int 1992; 2: 285-289.
21. De Greon PC, Lubbe DF, Hirsch LJ et al. Esophagitis associated with the use of alendronate. N Engl J Med, 1996; 335:1016.
22. Delmas P, Bjarnason NH, Mithak BH, Ravoux AC, Shah A, Huster WJ, Draper M, Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337:1641.
23. Dolan e cols. The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int, 1998; 8:611-7.
24. Duan Y, Tabensky A, Deluca V & Seeman E. "The benefit of hormone replacent therapy on bone mass in greater at the vertebral body than posterior processes or proximal femur". Bone. 1997; 21(5):447-51.
25. Epstein O, Kato Y, Dick R, Sherlock S. A prospective randomized trial of vitamin D, microcrysttalline hydroxyapatite compoud (MCHC) and calcium gluconate in the treatment of cortical bone thinning in post-menopausal women with primary biliary cirrhosis. Am J Clin Nutr. 1982; 36:426-30.
26. Estepán JJ, Pospinchal J Pacovsky V. Prospective trial of ossein-hydroxyapatite compound surgically induced postmenopausal women. Bone, 1989; 10:179-85.
27. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Gerant HK, et al. Redution of vertebral fracture risk in postmenopausal women with osteoporosis treated with reloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of reloxifene Evaluation (MORE) Investigators. Jama, 1999; 18;282(7):637.
28. Ettinger B, Genant HK, Cann CE,. Long term estrogen replacent therapy prevents bone loss and fractures. Ann Intern Med. 1985; 102:319-24.
29. Ettinger B, Genant HK, Cann CE,. Postmenopausal bone loss is prevented by treatment with low dosage estrogen with calcium. Ann Intern Med. 1987; 106:40-6.
30. Ettinger, B, Cann, L, Genant, K. Menopausal bone loss: effects of conjugated oestrogen and high calcium diet. Maturitas, 6:108, 1984.
31. European Communities/European Fondation for Osteoporosis. Building strong bones and preventing fractures: Summary report on osteoporosis in the European Community, 1998.
32. Falch JA, Odegaard OR, Finnanger M, Mathaeson I. Postmenopausal osteoporosis: no effect of three years treatment with 1,25-dihydroxycholecalciferol. Proc Soc Exp Biol Med, 1991 ; 191:987.
33. Fernandes CE, Ribeiro RM, Melo NR, Pinotti M. Osteoporose. Rev. Bras Med, 1995; 52(10); 1170-86.
34. Fernandes CE, Wehba S, Melo, NR, Ferreira JAS, Roucourt S, O metabolismo össeo e a osteoporose pós-menopáusica. O climatério e a Menopausa. Fascículo 4, 2000.
35. Fernandes CE, Machado RD, Melo NR, Wehba S, Ferreira JAS. Osteoporose: Rev. Bras. Med., 2000; 57:177-92.
36. Fleisch I. Bisphosphonates: pharmacology and use in the treatment of tumor induced hypercalcemia and metastatic bone disease. Drugs, 1991 ; 42:919-44.
37. Francis MD & Martodam RR. Chemical, biochemical and medicinal properties of the disphosphonates. Hildebrand, R. L. The role of Phosphonates in Living Systems. Boca Raton, CRC Press, 1983, pp. 55-96.
38. Freitas AL, Ribeiro Ana, Cardoso RM, Halbe HW, Sakamoto LC, Borelli A. Influência da idade e do índice de massa corpórea sobre a densidade mineral óssea do colo do femur e da coluna lombar em mulheres brasileiras com idade entre 45 e 80 anos. Rev Med, 1998; 77(1): 31-44,
39. Gallagher JC, Goldgar D. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol: a randomized controlled study. Ann Interm Med, 1990; 113:649.
40. Gallagher JC, Riggs BL, Recker RR, Goldgar D. The effects of cacitriol on patients with postmenopausal osteoporosis with special reference to fracture frequency. Roc Soc Exp Biol Med, 1989; 191:287.
41. Halbe HW, Mantese JC, Lopes CMC, Celestino CA, Pinotti JA,. Osteoporose Rev Med, 1993; 50.
42. Harris ST, Watts NB, Gerant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis - A randomized controlled trial. Jama, 1999; 282 (14):1344-52.
43. Hart, DM, Abdala, H, Clark, DM. Preservation of bone mass in postmenopausal women during therapy with estrogen and progestogens. In: Christiansen, C, Arnoud, CD, Nordin, BEC. (eds). Osteoporosis: proceedings of the Copenhagen International Symposium on osteoporosis. Copenhagen: Aalborg Stitfborgtrykeri, 1984; P. 697.
44. Heikinnheimo RJ, Inkovaara JA, Harju EJ, Haavisco MV, Kaarela RH, Kataja JM, Kokko AM, Kolho LA, Rajala S. Annual injection of vitamin D and fractures of aged bones. Calcif tissue Int, 1992; 51:105.
45. Hosking DJ, Eusebio RA, Chinesaa. Paget's disease of bone: reduction of disease activity with oral risedronate. Bone, 1998; 22:51-5.
46. Hughes DE, Wright KR, Uy HL, et al. Biphosphonates promote apoptosis in murine osteoclasts in vitro. J Bone miner Res, 1995; 10:1478.
47. Jensem, GF, Christiansen, C.Transbol, I. Treatment of postmenopausal osteoporosis. A controlled therapeutic trial comparing oestrogen/gestagen 1,25 dihydroxyvitamin D3 and calcium. Clin Endocrinol, 1982; 16:515.
48. Konsensus-Koferenz: Diagnose, profhylaxe und behandlung der osteoporose. Munc Med Wschr. Suppl, 1993; 108:6.
49. Krolner, B, Toft, B. Vertebral bone loss: and unheeded side effect of therapeutic bed rest. Clin Sci, 1983; 64:537.
50. Kudlacek S, Schneider B, Resch H, Wilvonseder R. Lumbar bone density. Risk factor for fractures in waren vertebral. Disch Med Wochenschur, 1998; 123(21): 651-7.
51. Liberman UA, Weiss SR, Broll J, et al. Effect of an oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med, 1995; 333:1437.
52. Lindsay R, Hart CM & Clark DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet. Gynecol, 1983; 63:759-63.
53. Lindsay, R, Hart, DM, Aitken, JM, Anderson, JB. Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bose mass after delayed onset of ostrogem treatment. Lancet, i may 15; 1(7968): 1038-41, 1976.
54. Lindsay, R, Hart, DM, Clark, DM. The minimum effective dose os estrogen for prevention of postmenopausal bone loss. Obstet Gynecol, 1984; 63: 759.
55. Lindsay, R, Hart, DM, Forrest, C, Baird, C. Prevention os spinal osteoporosis in oophorectomized women. Lancet 29, 2(8205): 1159-4, 1980.
56. Linsay, R, Hart, Dm, Kraszewski, A. A prespective double-blind trial of syntetic steroid (Org OD 14) for preventing post menopausal osteoporosis. Br Med J, 1980; 280:1027.
57. Lips P,. Epidemology and predictors of fractures associated with osteoporosis. Am J Med, 1997; 103(2A):3S-8S.
58. Mackintyre, I, Stevenson, JC, Whitehead, MI. Calcitonin for prevention of postmenopausal bone loss. Lancet Apr 23,; 1(8591): 900-2, 1988.
59. Melton LJ III. Epidemiology of spinal osteoporosis. Spine, 1997;22(24suppl):2S-11S.
60. Miller PD, Brown JP, Siris ES, et al. A comparative trial of risedronate versus etidronate in the treatment of patients with. Paget's disease of bone. Am J Med, 1999; 106:513-20.
61. Mortensen L, Charles P, Bekker PJ, et al. Rise-dronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab, 1998; 83:396-402,.
62. NIH Consensus Development Panel on Optinal Calcium Intake, Optimal calcium intake, Jama, 1994; 272:1942.
63. NIH Consensus Development Conference Statement, Osteoporosis, Prevention, Diagnosis, and Therapy, 2000.
64. Notevolitz M. Stxercise and health maintenance in menopausal women. Ann. NY Acad. Sci., 1990; 592:204-20.
65. Ooms ME, Roos JC, Bezemer PD, Wim JF, Van Der Vijgh JF, Bouter LM, Lips P. Prevention of bone loss by vitamin D supplementation in elderly women: a randomized double-blind trial. J Clin Endocrinol Metab, 1995, 80:1052.
66. Oritmo H, Shiraly M, Hayshi T, Nakamura T. Reduced occurence of vertebral crush fractures in senile osteoporosis treated with 1 alpha (OH) -vitamin D. Bone Miner, 1987; 3:47.
67. Osteoporosis 1995. Basic diagnosis and therapeutic elements for a "National Consensus Proposal". São Paulo Medical Journal, 1983; p.54.
68. Ott SM, Chesnutt C. Calcitriol treatment is not effective in osteoporosis. Ann Interm Med, 1989; 84:267.
69. Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effects of salcatonin given intra-nasally on bone mass and fractures rates in established osteoporosis: a dose-response study. Br Med J, 1992; 303:556.
70. Parfitt AM, Mundy GR, Roodman GD, Hughes DE, Boyce BF. A new model for the regulation of bone resoption, with particular reference to the effects of bisphosphonates. J Bone Miner Res, 1996; 11:150.
71. Parfitt AM. The celular basis of bone remodeling. The quantum concept reexamined light of recent advances in cell biology of bone. Cacif Tissue Int, 1984; 36:537.
72. Prince RL, Smith M, Dick IM, et al. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy. N Engl J Med 325 (17): 1189-95, 1991.
73. Quiqley, MET, Martin, PL, Burnier, AM. Estrogen therapy arrest bone loss in elderly women. Am J Obstet Gynecol, 1987; 156:1516.
74. Ray e cols. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995; report from the National Osteoporosis Foundation. J Bone Miner Res, 1997; 12:24-35.
75. Recke R, Kimmmel DM, Hiders S, Davies KM. Antifracture efficacy of calcium in elderly women. J Bone Miner Res, 1994; 9 (suppl):135.
76. Reginster, JY, Denis, D, Albert, A. 1-year controlled randomized trial of prevention of early postmenopausal bone loss by intrasanal calcitonin. Lancet, 1987;ii:1481.
77. Reld IR, Ames RW, Evans MC, et al. Long terms effect of calcium supplementation on bone loss and fractures in postmenopausal women - a randomized controlled trial. Am J Med, 1995; 98:331.
78. Ribot, C, Tremollieres Pouilles, JM, Louvt, JP. Preventive effects os transdermal administration of 17 β-estradiol on postmenopausal bone loss: A 2-year prospective study. Obst Gynecol, 1990; 75 (suppl):425.
79. Riggs, BL, Pathogeneses of osteoporosis. Am J Obstet Gynecol, 1987;156(5):1342.
80. Riis B, Thomsen K, Christiansen C. Does calcium supplementation prevent postmenopausal bone loss. N Engl J Med, 1987; 316:173-176.
81. Ross PD, Davis JW, Eptein RS, Wasnich RD. Preexisting fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med, 1991; 114:919-23.
82. Roux C, Ravaud P, Cohen-Solal M, et al. Biologic, histologic and densitometric effects cf oral risedronate on bone in patients with multiple myeloma. Bone, 1994; 15:41-9.
83. Ruegsegger P, Keller A, Dambacher MA. Comparison of the treatment effects of ossein-hydroxyapatite compoud and calcium carbonete in osteoporotic females. Osteoporos Int. 1995; 5:30-4.
84. Sato M, Bryant HU, Iversen P, Helterbrandj, Smietana F, Bemis K, Higgs R, Turner CH, Owan I, Takano Y, Burr BD. Advantages of raloxifene over alendronate or estrogen on non reproductive tissues in the long term dosing of ovariectomized rats. Pharmacol Exp Ther 1996; 279:98.
85. Sakamoto LC, Halbe HW. Epidemiologia da menopausa. In: Menopausa. Pinotti JA, Halbe HW, Hegg R. Roca p. 1-9, 1995.
86. Schnitzer T, Bone HG, Crepaldi G et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res, 2000; 12:1-12.
87. Simkin A. Increase trabecular bone density due to bone-loading exercises in postmenopausal osteoporotic women. Calcif Tissue Int., 1987; 40:59-63.
88. Smith EL & Smith PE. Bone involution decrease in exercinsing middle aged women. Calcif Tissue Int., 1984, 36: 5129-3138.
89. Singer BR, Mc Lauchlan GJ, Robinson CM, Christie J. Epidemiology of fractures in 15.000 adults: the influence of age and gender. J Bone Joint Surg Br, 1998; 80(2): 243-8.
90. Stevenson, JC, Whitehead, Ml, Padwick, M et al. Dietary intake of calcium and postmenopausal bone loss. Br Med J, 1988; 297:15.
91. Szejnfeld VL, De Lima GR, Atra E. Osteoporose no climatério. In: Menopausa. Pinotti JA, Halbe HW, Hegg R. Roca, 1995; p 189-211.
92. Tilyadr MW, Spears GFS, Thomson J, Dovey S. Treatment of Postmenopausal osteoporosis with calcitriol vs calcium. New Engl J Med, 1992; 326:357.
93. Tsai KS. Osteoporotic fracture rate, bone mineral density, and bone metabolism in Taiwan. J Formos Med Assoc, 1997; 96(10): 802-5.
94. Tucci JR. Osteoporosis update. Med Health R I, 81(5):169-73.
95. Who study group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series no 843. Geneva: world Health Organization, 1994; 1-129.
96. Uusi-Rasi K et al. Associations of physical activity and calcium initake with bone mass and size in healthy women at different ages. J. Bone Miner. Re., 1998; 13(1): 133-142.
97. Weiss NS, Ure CL, Ballard JH, Williams AR & Dalim JR. Decreased risk of the hip and lower forearm fracture with postmenopausal use of estrogen. N. Engl. J. Med. 1980; 303:1195-8.
98. Wimalawansa SJ. Combined therapy with estrogen and etdronatehas an additive effect on bone mineral density in the hip and vertebrae: four year randomized study. Am J Med, 1995; 99:36.